The Europe cancer diagnostics market refers to the industry related to detecting and diagnosing cancer in European countries. It encompasses a range of medical procedures, technologies, and equipment used to detect, identify, and assess cancer in patients. This market focuses on the various diagnostic methods and tools available, including imaging techniques, blood tests, and biopsies, to enable accurate cancer diagnosis and inform treatment decisions, contributing to improved patient outcomes.
Access full Report @ https://www.databridgemarketresearch.com/reports/europe-cancer-diagnostics-market
Data Bridge Market Research analyses that the Europe Cancer Diagnostics Market is expected to grow at a CAGR of 6.80% during the forecast period of 2023 to 2030 and is expected to reach USD 31,093.51 million by 2030 from USD 18,369.60 million in 2022. The escalating incidence of cancer is a pivotal factor driving the demand for diagnostic solutions and early detection methods. As cancer cases continue to rise, there is a pressing need for effective and timely diagnostic tools to facilitate prompt and precise intervention, ultimately improving patient outcomes.
Key Findings of the Study
Personalized medicine is expected to drive the market's growth rate
Personalized medicine is revolutionizing healthcare by tailoring treatment plans to individual patient's unique genetic and molecular profiles. This approach relies on precise diagnostics to determine the most effective therapies, minimizing side effects and improving outcomes. As a result, the Europe cancer diagnostics market is experiencing significant growth. Patients benefit from treatments that are more effective and better tolerated, enhancing their overall quality of life. Healthcare providers and pharmaceutical companies are increasingly investing in advanced diagnostic technologies and therapies, creating a positive feedback loop that propels market expansion and the realization of the promise of personalized medicine in cancer care.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Instrument, Consumables and Accessories, Software and Service), Test Type (Imaging, Biopsy, Tumor Biomarkers Tests, Genetic Tests, Endoscopy, Immunohistochemistry, Others), Technology (Instrument Based, Platform-Based, Tumor Biomarker Tests), Application (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Skin Cancer, Kidney Cancer, Blood Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Others), Age Group (Adult, Pediatric), End-User (Hospitals, Oncology Speciality Clinics, Diagnostic Laboratories, Cancer Research Institutes, Others), Distribution Channel (Direct tenders, Retail Sales).
|
|
Countries Covered
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
|
|
Market Players Covered
|
General Electric (U.S.), Abbott (U.S.), Hologic Inc. (U.S.), Agilent Technologies Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), FUJIFILM Corporation (Japan), Danaher (U.S.), DiaSorin S.P.A. (Italy), Myriad Genetics Inc. (U.S.), Siemens Healthcare GmbH (Germany), BD (U.S.), bioMérieux (France), Bio-Rad Laboratories Inc. (U.S.), Cancer Diagnostics Inc. (U.S.), Vela Diagnostics (Singapore), AMOY Diagnostics CO. LTD. (China), Quidel Corporation (U.S.), Bio SB (U.S.), Biocartis (Belgium), Exact Science (U.S.).
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Europe cancer diagnostics market is segmented on the basis of product type, test type, technology, application, age group, distribution channel, and end-user.
- On the basis of product type, the Europe cancer diagnostics market is segmented into instrument, consumables and accessories, software and service
- On the basis of test type, the Europe cancer diagnostics market is segmented into imaging, biopsy, tumor biomarkers tests, genetic tests, endoscopy, immunohistochemistry, and others
- On the basis of technology, the Europe cancer diagnostics market is segmented into instrument based, platform-based, and tumor biomarker tests
- On the basis of application, the Europe cancer diagnostics market is segmented into breast cancer, prostate cancer, colorectal cancer, lung cancer, skin cancer, kidney cancer, blood cancer, pancreatic cancer, ovarian cancer, cervical cancer, and others
- On the basis of age group, the Europe cancer diagnostics market is segmented into adult, and pediatric
- On the basis of end-user, the Europe cancer diagnostics market is segmented into hospitals, oncology speciality clinics, diagnostic laboratories, cancer research institutes, and others.
- On the basis of distribution channel, the Europe cancer diagnostics market is segmented into direct tenders, and retail sales
Major Players
Data Bridge Market Research recognizes the following companies as the major Europe cancer diagnostics market players in Europe cancer diagnostics market are General Electric (U.S.), Abbott (U.S.), Hologic Inc. (U.S.), Agilent Technologies Inc. (U.S.), F.Hoffmann-La Roche Ltd (Switzerland), FUJIFILM Corporation (Japan), Danaher (U.S.), DiaSorin S.P.A. (Italy), Myriad Genetics Inc. (U.S.).
Market Developments
- In January 2022, Roche announced its acquisition of a leading Europe cancer diagnostics company, enhancing its molecular testing capabilities. This strategic move aims to bolster early cancer detection efforts and improve patient outcomes, reflecting the market's trajectory driven by innovative collaborations and acquisitions shortly
- In November 2021, Roche announced the acquisition of a leading European cancer diagnostics company, further strengthening its presence in the market. This strategic move is expected to drive innovation, expand its diagnostic portfolio, and fuel substantial growth in the segment in the coming years
- In November 2021, Roche announced its acquisition of a prominent European cancer diagnostics company, bolstering its presence in the Europe cancer diagnostics market. This strategic move is expected to drive innovation and growth in the segment due to the expanded capabilities and resources resulting from this acquisition
Regional Analysis
Geographically, the countries covered in the Europe cancer diagnostics market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
As per Data Bridge Market Research analysis:
Germany is the dominant region in Europe cancer diagnostics market during the forecast period 2023-2030
Germany dominates the market due to its high cancer rates widespread diagnostic systems, and consumables availability. The country's advanced healthcare infrastructure caters to the prevalent cancer cases. This accessibility, coupled with a high incidence of cancer among the population, contributes to Germany's dominant position in the market.
For more detailed information about the Europe cancer diagnostics market report, click here – https://www.databridgemarketresearch.com/reports/europe-cancer-diagnostics-market
